Zhang Wenjing, Li Long, Wang Zishuo, Nie Yangyi, Yang Yipei, Li Cairong, Zhang Yuyang, Jiang Yuxi, Kou Yuhui, Zhang Wei, Lai Yuxiao
Shenzhen Clinical Research Center for Trauma Treatment, Shenzhen University General Hospital, Shenzhen University, Shenzhen, 518055, China; Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, National-Regional Key Technology Engineering Laboratory for Medical Ultrasound, School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen, 518060, China; National Center for Trauma Medicine, Beijing, 100000, China.
Centre for Translational Medicine Research & Development, Institute of Biomedical and Health Engineering, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China; Guangdong Engineering Laboratory of Biomaterials Additive Manufacturing, Shenzhen, 518055, China.
Biomaterials. 2025 Apr;315:122959. doi: 10.1016/j.biomaterials.2024.122959. Epub 2024 Nov 20.
The clinical treatment of osteosarcoma faces great challenges of residual tumor cells leading to tumor recurrence and irregular bone defects difficult to repair after surgery removal of the primary tumor tissue. We developed an injectable and in-situ cross-linkable hydrogel (named MOG hydrogel) using MgO nanoparticles and dopamine-conjugated gelatin as main components. MgO was rationally designed as a multifunctional active ingredient to mediate in situ gelation, tumor therapy, and bone repair sequentially. The 10MOG (with 10 mg/mL MgO content) showed excellent gel stability, injectability, shape adaptability, tissue adhesion, and rapid hemostatic ability. Importantly, 10MOG exhibited ideal sequential HO and Mg release property. The released HO synergized with photothermal therapy for enhanced tumor recurrence suppression, and the sustainable Mg release efficiently promoted bone regeneration. The MOG hydrogel, possessing excellent on-demand antitumor and osteogenic capabilities in vitro and in vivo, exhibited tremendous potential in the clinical application for challenging postsurgical osteosarcoma treatment.
骨肉瘤的临床治疗面临着巨大挑战，即残留肿瘤细胞会导致肿瘤复发，且在手术切除原发性肿瘤组织后会出现难以修复的不规则骨缺损。我们以氧化镁纳米颗粒和多巴胺共轭明胶为主要成分，开发了一种可注射且能原位交联的水凝胶（命名为MOG水凝胶）。氧化镁被合理设计为一种多功能活性成分，依次介导原位凝胶化、肿瘤治疗和骨修复。10MOG（氧化镁含量为10mg/mL）表现出优异的凝胶稳定性、可注射性、形状适应性、组织粘附性和快速止血能力。重要的是，10MOG表现出理想的顺序性羟基自由基（HO）和镁释放特性。释放出的HO与光热疗法协同作用，增强对肿瘤复发的抑制，而镁的持续释放有效促进骨再生。MOG水凝胶在体外和体内均具有出色的按需抗肿瘤和成骨能力，在具有挑战性的骨肉瘤术后治疗的临床应用中展现出巨大潜力。
